Illumina (ILMN) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Illumina (ILMN) quarterly earnings & revenue
Illumina (ILMN) reported revenue of $1.09B for Q1 2026, up 4.8% year-over-year, with net income of $134.00M and diluted EPS of $0.87.
Over the last four reported quarters, Illumina generated $4.39B in revenue and $853.00M in net income.
Illumina's next earnings report is scheduled for July 30, 2026 after market close; analysts estimate EPS of $1.24.
Illumina quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $1.09B | +4.8% | $134.00M | $0.87 |
| Q4 2025 | $1.16B | +5.1% | $334.00M | $2.17 |
| Q3 2025 | $1.08B | +0.3% | $150.00M | $0.97 |
| Q2 2025 | $1.06B | -4.9% | $235.00M | $1.50 |
| Q1 2025 | $1.04B | -3.3% | $131.00M | $0.82 |
| Q4 2024 | $1.10B | -1.6% | $187.00M | $1.17 |
| Q3 2024 | $1.08B | -3.5% | $705.00M | $4.41 |
| Q2 2024 | $1.11B | -5.4% | $-1.99B | $-12.50 |
Illumina (ILMN) — frequently asked questions
When does Illumina (ILMN) report earnings next?
Illumina is expected to report earnings on July 30, 2026 after market close. Analysts estimate EPS of $1.24.
What was ILMN's revenue last quarter?
Illumina reported revenue of $1.09B in Q1 2026, up 4.8% from the same quarter a year earlier.
What was ILMN's EPS last quarter?
Illumina reported diluted EPS of $0.87 in Q1 2026.
Is Illumina profitable?
Illumina is currently profitable, with $853.00M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)